Development of an in-vivo active reversible butyrylcholinesterase inhibitor. - Archive ouverte HAL Access content directly
Journal Articles Scientific Reports Year : 2016

Development of an in-vivo active reversible butyrylcholinesterase inhibitor.

Urban Košak
  • Function : Author
Boris Brus
  • Function : Author
Damijan Knez
  • Function : Author
Roman Šink
  • Function : Author
Anja Pišlar
  • Function : Author
Jasna Šlenc
  • Function : Author
Kinga Sałat
  • Function : Author
Barbara Malawska
Janko Kos
  • Function : Author


Alzheimer's disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD.

Dates and versions

hal-01465678 , version 1 (13-02-2017)



Urban Košak, Boris Brus, Damijan Knez, Roman Šink, Simon Žakelj, et al.. Development of an in-vivo active reversible butyrylcholinesterase inhibitor.. Scientific Reports, 2016, 6, pp.39495. ⟨10.1038/srep39495⟩. ⟨hal-01465678⟩
183 View
0 Download



Gmail Facebook Twitter LinkedIn More